Astudal

Quick links to important sections

Astudal

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astudal

What is Astudal? Overview

Property Description
Active ingredient Amlodipine besilate (Amlodipine)
Form Tablet (Oral preparation)
Pharmacological class Calcium Channel Blocker (CCB)
General purpose Management of high blood pressure and chest discomfort (angina)
Origin Synthetic compound

Defining Astudal: Type, Active Ingredient, and Origin

Astudal is a prescription medicine intended for the long-term management of cardiovascular conditions, available as a synthetic, single-ingredient oral preparation in tablet form. Its core chemical entity is Amlodipine besilate (Amlodipine), a compound clinically recognized for its sustained efficacy in regulating vascular tone.

Amlodipine is definitively classified as a Calcium Channel Blocker (CCB), specifically falling within the dihydropyridine subclass. This second-generation dihydropyridine is characteristically long-acting, a distinction important for facilitating once-daily dosing and ensuring consistent therapeutic presence.

What Classification of Medicine is Amlodipine?

Amlodipine functions principally as an antihypertensive agent and an antianginal agent. Its mechanism centers on selective inhibition of calcium ion influx into the smooth muscle cells of the blood vessels. This widening of vessels (vasodilation) is key to the drug's intended action. This function as a peripheral vasodilator is its defining action, resulting in the reduction of mechanical resistance in the circulatory system.

General Purpose of Astudal: Managing Vascular Function

The overall therapeutic purpose of Astudal is the mitigation of cardiovascular strain by reducing peripheral vascular resistance. This effect decreases the workload on the heart, serving as the core mechanism for controlling elevated High blood pressure (Hypertension). Furthermore, the drug promotes the widening of coronary arteries, a physiological effect that improves the supply of oxygenated blood to the heart muscle, providing essential support in managing conditions like Chronic stable angina and Vasospastic angina (Prinzmetal’s angina).

Regulatory References

  1. Amlodipine - StatPearls - NCBI Bookshelf
  2. Norvasc - referral | European Medicines Agency (EMA)
  3. European Medicines Agency documentation

What side effects are possible with Astudal?

Possible Side Effects and Safety Information

The safety profile of Astudal (Amlodipine) is defined by regulatory bodies through classification of potential adverse reactions based on the body system affected and their reported frequency. The official documentation identifies common, less common, and rare events, with some effects noted as more likely to appear at the start of treatment or during dose changes.

Classification of Officially Documented Adverse Reactions

The most frequently reported adverse reactions, classified as Common (affecting 1 in 10 to 1 in 100 people), include headache, somnolence (drowsiness), dizziness, palpitations, flushing, abdominal pain, and oedema (swelling), particularly of the ankles. This ankle oedema is noted as an effect that appears to be dose-related, increasing in incidence at higher daily doses.

Uncommon effects may involve the skin, psychiatric state, and musculoskeletal system, including mood changes, rash, pruritus, and muscle pain. Effects such as headache and dizziness are often reported at the beginning of the treatment.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents potential Very Rare serious adverse reactions (affecting less than 1 in 10,000 people). These may involve the hepatobiliary system, including cases of hepatitis and jaundice, and severe skin reactions such as angioedema and erythema multiforme. Additionally, the possibility of symptomatic hypotension exists, notably in individuals with underlying conditions like severe aortic stenosis.

Specific safety considerations exist for certain populations. Patients with severe hepatic impairment may experience decreased clearance, which results in a prolonged elimination half-life. Clearance is also decreased in older adults, leading to increased drug exposure.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The most significant and documented manifestation of Astudal (Amlodipine) overdose is profound and prolonged systemic hypotension, which results from excessive peripheral vasodilation [2.1]. This severe decrease in blood pressure may rapidly progress to life-threatening shock and cardiovascular collapse [2.6].

Documented Overdose Manifestations and Severe Outcomes:

Clinical Sign/Symptom Severe Outcome
Profound Hypotension [2.1] Shock [1.8]
Bradycardia or Tachycardia [1.8] Cardiovascular Collapse [2.6]
Dizziness or Somnolence [1.8] Death [2.5]

Required Emergency Action

The official guidance mandates that any suspected overdose requires that a patient seek immediate medical attention [1.8]. Because Amlodipine has a long elimination half-life, continuous monitoring and extended observation in a hospital setting may be required, even in less severe cases [2.1].

Management and Monitoring

Management is primarily symptomatic and supportive. Due to the high risk of life-threatening instability, active cardiac and respiratory monitoring are necessary [2.1]. Documented supportive procedures include the use of intravenous fluids, vasopressors, and calcium infusion [2.3]. No specific antidote is definitively established in regulatory labeling, underscoring the reliance on aggressive supportive care [2.3]. Individuals with pre-existing health conditions or those who have co-ingested other cardiac-acting drugs may face an increased risk of severe outcomes [1.8].

Therapeutic Uses of Astudal

What Astudal Treats: Main Uses and Benefits

Astudal is a prescription medicine commonly used to manage chronic cardiovascular conditions, focusing on maintaining stable vascular function and providing support that helps ease the overall symptom burden. The medication may be part of symptomatic management across key therapeutic areas, assisting with maintaining functional stability.

Sustained Management of Chronic High Blood Pressure

Astudal is centrally used for the management of conditions marked by increased physiological stress, specifically concerning systemic blood pressure. This addresses the chronic condition of persistently elevated pressure, which creates noticeable physiological strain and requires daily support. The primary benefit is in supporting the management of symptoms related to systemic imbalance, which helps reduce the overall vascular strain and contributes to easing the overall symptom load.

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, and may be applicable in contexts involving Hypertension, Chronic Stable Angina, and Vasospastic Angina.

Reducing Recurrent Angina Chest Discomfort

This medication provides supportive therapeutic benefit by addressing symptoms related to heightened physiological activity, particularly recurrent chest discomfort. It is applied across domains where additional symptomatic support is needed for managing established angina. The key benefits may include assistance with managing symptoms associated with acute or episodic changes and the potential to assist with maintaining functional stability during symptomatic periods.

“This medication is considered relevant in contexts involving heightened systemic burden and assists with maintaining functional stability during symptomatic periods.”

Quick Fact: Relief for Chest Discomfort

Astudal is considered relevant for easing symptoms related to episodic or fluctuating manifestations, particularly the recurrent chest discomfort associated with angina, and supports the patient when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview on Amlodipine

Eligibility and Restrictions for Use

Astudal (amlodipine besilate) eligibility is determined by official regulatory criteria concerning age, specific conditions, and physiological status, as defined in government-approved labeling documents.

Contraindicated Populations

Use of Astudal is strictly contraindicated in patients with:

  • Known hypersensitivity to Amlodipine, other dihydropyridine derivatives (its drug class), or any component of the formulation.
  • Severe hypotension.
  • Shock (including cardiogenic shock).
  • Obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
  • Haemodynamically unstable heart failure following an acute myocardial infarction.

Age-Related Eligibility

Age Group Eligibility Status (Official Wording)
Adults (18+ years) Approved for labeled indications (hypertension and angina).
Children (6–17 years) Approved for hypertension only. Doses above 5 mg daily have not been studied.
Children (Under 6 years) Safety and efficacy have not been established for hypertension; use is generally not recommended.
Elderly Patients Permitted, but dosage increase should occur with care.

Conditional Use and Restrictions

  • Hepatic Impairment: Patients with liver problems should be started on the lowest initial dose and titrated slowly due to prolonged drug clearance.
  • Renal Impairment: Normal dosage is generally recommended as changes in drug plasma concentrations are not correlated with the degree of impairment.
  • Pregnancy: Use is recommended only if the potential benefit justifies the potential risk to the mother and fetus.
  • Lactation: Amlodipine is present in breast milk; a decision must be made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Astudal's active ingredient, amlodipine, can interact with various medications and products, potentially altering the drug's effectiveness or increasing the risk of side effects, such as very low blood pressure (hypotension) or fluid retention (edema).

It is essential to inform a healthcare professional about all prescription and non-prescription medicines, vitamins, herbal supplements, and foods being consumed.

Common Interaction Categories

Drug Category Potential Effect on Astudal or Co-administered Drug
Strong CYP3A4 Inhibitors (e.g., some antifungals, certain HIV protease inhibitors, macrolide antibiotics like clarithromycin) May significantly increase Astudal levels in the blood, increasing the risk of adverse effects.
CYP3A4 Inducers (e.g., rifampicin, St. John's Wort) May decrease the concentration of Astudal in the blood, potentially reducing its therapeutic effect.
Other Blood Pressure Medications (e.g., beta-blockers, ACE inhibitors, diuretics) Additive blood pressure lowering effects, increasing the risk of symptomatic hypotension.
Simvastatin (a cholesterol-lowering medication) Astudal may increase the blood levels of Simvastatin, raising the risk of muscle-related side effects.
Immunosuppressants (e.g., cyclosporine, tacrolimus) Astudal may increase the blood levels of these agents, requiring dose monitoring.

Food and Product Interactions

Consumption of grapefruit or grapefruit juice should be avoided. These products can increase the systemic exposure of Astudal, leading to an unpredictable enhancement of its blood pressure-lowering effect and a heightened risk of side effects. The consumption of large quantities of alcohol may also increase the risk of low blood pressure and dizziness when taken with Astudal.

Mechanism of Action

Core Mechanism: Blocking L-Type Calcium Channels

Astudal acts as an inhibitor by binding to and blocking voltage-dependent L-type calcium channels (Cav1.2). These channels are primarily located on the membranes of vascular smooth muscle cells. This molecular interaction prevents the transmembrane influx of extracellular calcium ions (Ca^2+) into the smooth muscle cell cytoplasm. The resulting deficit in intracellular Ca^2+ inhibits the excitation-contraction coupling cascade, leading directly to vascular smooth muscle relaxation (vasodilation).

Physiological Outcome: Reduction in Systemic Resistance

The resulting widespread vasodilation across the peripheral arterial network causes a significant decrease in total peripheral resistance (TPR), also known as afterload. This system-level physiological modulation reduces the force required for ventricular ejection, altering cardiac workload. Astudal demonstrates a pronounced selectivity for peripheral vascular channels over those in the cardiac conduction system, focusing its action on the arterial tone and contributing to the observed decrease in arterial blood pressure.

Dosage and Administration Information

How to Use Astudal (Amlodipine) — Administration Guidelines

This information details the administration instructions for Astudal (amlodipine) and should not be interpreted as medical advice.

Standard Dosing and Administration

Astudal is approved for oral administration as a tablet, available in strengths such as 2.5 mg, 5 mg, and 10 mg. The medicine is typically taken once daily.

Component Instruction
Route of Administration Oral
Adult Initial Dose 5 mg once daily
Adult Maximum Dose 10 mg once daily
Timing with Meals May be taken with or without food

Dose adjustments, or titration, are often conducted over a period of 7 to 14 days to fully gauge the treatment response before increasing the daily amount.

Procedural and Population-Specific Rules

Patients should take the tablets at approximately the same time each day to maintain consistent medication levels. If a dose is missed, it should be taken as soon as remembered on that day; however, if a full day has passed, the missed dose should be skipped, and the patient should return to the normal schedule (do not take two doses to make up for one).

Population-Specific Dosing:

  • Elderly or Frail Patients: A lower initial dose of 2.5 mg once daily is recommended.
  • Hepatic Impairment: Patients with liver function impairment should also start with a reduced dose of 2.5 mg once daily.
  • Pediatric Patients (6–17 years): The prescribed dose is typically between 2.5 mg and 5 mg once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Astudal


Evidence for Use in High Blood Pressure (Hypertension)

Research concerning Astudal was evaluated in studies of high blood pressure, or hypertension, in a variety of large-scale, long-duration Randomized Controlled Trials (RCTs) and systematic reviews. These studies structured comparisons between amlodipine, the active ingredient in Astudal, and both placebo and other established drug classes. Researchers examined both short-term outcomes related to mean changes in blood pressure readings and long-term health metrics over several years.

Long-term studies monitored specific endpoints, such as the time until a major cardiovascular event, including a non-fatal stroke or heart attack, was observed. Studies reported measurements of the incidence of these events over follow-up periods that typically ranged from three to six years. Evidence for direct comparison between Astudal and all other drug classes across all specific subgroups remains limited, as findings can be heterogeneous.


Evidence for Use in Chronic Stable and Vasospastic Angina

Astudal was studied in controlled clinical trials exploring conditions characterized by episodic manifestations, specifically chronic stable angina and vasospastic angina. For chronic stable angina, research explored changes measured during the study period, such as the time until an exercise test had to be stopped due to symptoms. Studies also monitored patient-reported outcomes describing perceived discomfort, specifically the measured change in the frequency of weekly chest discomfort attacks.

The majority of these studies were designed to measure changes in symptoms and functional measures over intermediate follow-up durations, typically weeks or a few months. Therefore, evidence related to long-term major cardiovascular events specific to the angina indication remains less established than for the hypertension indication.


Evidence in Specific Patient Populations and Research Gaps

Research has evaluated Astudal in specific patient groups, including children and adolescents aged 6 to 17 years with hypertension. Major outcomes trials also included a significant number of older adults and patients with comorbidities, such as those with diabetes mellitus. Data show patterns related to measured blood pressure changes in these groups.

One key limitation is that long-term outcomes are not fully established beyond the typical six-year follow-up of the largest trials. Certainty remains low for specific subgroups due to limited information, and sample sizes were modest in some of the shorter-term trials. The research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Astudal (FAQ)

Q: What drug class does Astudal belong to?

Astudal's active ingredient, amlodipine, belongs to the drug class known as calcium channel blockers. Official documents state that this class of medicine works by influencing the flow of calcium ions into certain cells in the body, primarily in the blood vessel walls.


Q: How is Astudal generally different from older medicines used for the same purpose?

Studies indicate that amlodipine has a prolonged duration of action and a long elimination half-life, typically ranging from 30 to 50 hours. This difference from some older medications in the same class allows it to be taken just once daily to maintain consistent levels in the body.


Q: Is Astudal meant to be a long-term or a short-term course of treatment?

According to patient information resources, Astudal is typically prescribed for long-term use, particularly for chronic conditions such as high blood pressure. Consistent, long-term use is generally required for the best therapeutic results.


Q: How long does it usually take for Astudal to show its expected effect?

Official regulatory information indicates that the blood pressure-lowering effect of a single dose occurs gradually. This process typically takes place over 4 to 8 hours following oral administration.


Q: Is Astudal typically prescribed to be taken for a defined period of time?

For chronic conditions like hypertension, Astudal is generally intended to be taken long-term without a set stopping date. The duration of therapy is a clinical decision based on the specific condition being managed.


Q: What are the signs of a possible allergic reaction to Astudal, as described in official documents?

Regulatory safety documents describe potential signs of an allergic reaction. These may include a rash, itchiness, or more severe signs such as swelling of the face, lips, or tongue, and difficulty breathing or wheezing.


Q: Does Astudal have any official warnings about potential impact on driving or operating machinery?

Official patient information cautions that Astudal may cause side effects like dizziness or somnolence (drowsiness). Official cautions recommend against driving or operating machinery until the patient is certain the medication does not impair their abilities.


Q: Do the common, minor side effects of Astudal typically lessen over time?

Official information suggests that certain minor effects, like headache and dizziness, are most commonly reported when treatment begins. These symptoms often improve or lessen over time as the body adjusts to the medication.


Q: Are there any known interactions between Astudal and common over-the-counter pain relievers?

Official interaction data indicates that amlodipine can interact with certain nonsteroidal anti-inflammatory drugs (NSAIDs), which are found in many common over-the-counter pain relievers (like ibuprofen). This interaction could potentially reduce the blood pressure-lowering effect of Astudal.


Q: Does Astudal interact with any specific foods or dietary supplements?

Official product information recommends avoiding the consumption of grapefruit or grapefruit juice while taking Astudal, as these can increase the drug’s concentration. Furthermore, caution is recommended when using multivitamin supplements that contain minerals, as these may decrease the medicine's effectiveness.


Q: Are there specific medical conditions that generally exclude someone from using Astudal?

Official regulatory documents state that the primary exclusion for using Astudal is a known hypersensitivity, or allergy, to amlodipine itself or to any other medication belonging to the dihydropyridine class.


Q: Where can I find the official regulatory document (like the patient information leaflet) for Astudal?

Official patient information, such as the Patient Information Leaflet, is published by national health regulatory bodies. These documents are generally available for public viewing on the websites of authorities such as the FDA (Food and Drug Administration) or the EMA (European Medicines Agency).


Q: Why do some people on forums report that Astudal causes vivid dreams or changes in sleep?

Official safety information documents list abnormal dreams and insomnia (difficulty sleeping) among the recognized, though uncommon, side effects of the medication.


Q: Is Astudal available in different formulations (e.g., liquid, extended-release, tablet)?

According to official sources, the active ingredient in Astudal (amlodipine) is manufactured in several oral formulations. These include a standard tablet, as well as an oral suspension and an oral solution.


Q: What are the long-term safety considerations for taking Astudal?

Astudal is an established medication that is often prescribed and studied for continuous long-term use in adults. All established potential side effects, including both common and very rare serious adverse reactions, are documented in the official safety information provided by regulatory bodies.


Q: Is special prescription authorization or specific monitoring generally required to receive Astudal?

While special authorization is not universally required, regulatory bodies recommend ongoing monitoring during treatment. This monitoring often includes periodic checks of blood pressure, liver function, and kidney function, especially for patients who have pre-existing health conditions.


Q: Is it possible for Astudal to lose its effectiveness if exposed to improper storage conditions like heat or light?

The official product monograph specifies that Astudal tablets must be stored at Controlled Room Temperature to ensure stability and quality. Exposure to temperatures outside of this range, such as excessive heat or light, may compromise the drug's integrity and potentially reduce its effectiveness.


Q: Is Astudal a brand-name or a generic medication?

Astudal is the brand name used in this context. The active pharmaceutical ingredient, amlodipine, is widely available as a lower-cost generic medication approved by regulatory agencies.


Q: Is it normal to feel no difference immediately after starting Astudal?

For patients taking Astudal for high blood pressure, it is normal to not feel any immediate change or difference, as the condition may not cause noticeable symptoms. Regulatory patient information notes that feeling no immediate change does not mean the medicine is ineffective.


Q: Is there information suggesting Astudal affects body weight (gain or loss)?

Official safety information includes reports of weight gain as a possible side effect of amlodipine. In some instances, this change in weight may be linked to fluid retention or swelling (edema), which is a commonly reported adverse reaction.


Q: Is it known if Astudal interacts with caffeine or other stimulant products?

Official drug interaction data suggests that amlodipine can potentially interact with products containing stimulants, including caffeine. Combining these products may sometimes enhance effects like increased blood pressure or heart rate.


Q: What does the regulatory information state about Astudal use during pregnancy?

Regulatory information states that use during pregnancy requires a careful review of risks and benefits. Patients who are pregnant or planning to be pregnant must consult a healthcare provider to review the risks and benefits.


Q: Is Astudal considered safe for use while breastfeeding, according to official sources?

Official patient information states that the active ingredient in Astudal passes into breast milk. Due to this finding, regulatory safety guidelines typically do not recommend the use of this medication while breastfeeding.


Q: Is a kidney function test typically required before starting Astudal treatment?

While not universally required for all patients, official monitoring guidelines recommend regular checks of kidney function, also known as renal function. This recommendation is particularly emphasized for patients who have pre-existing kidney issues.


Q: Does the required use of Astudal vary based on a patient's sex?

There are no sex-specific differences in required dosing, but clinical data does show some variance in reported side effects. For example, the common side effect of fluid retention (edema or swelling) has been reported to occur more frequently in women than in men.


Q: Is it true that Astudal is classified as a controlled substance in some regions?

According to the regulatory bodies that classify medications based on their potential for abuse or dependency, amlodipine is not classified as a controlled substance.


Q: Is it safe to crush or split Astudal tablets/capsules, as described in product information?

Specialized medication guidelines indicate that amlodipine tablets can be dispersed (crushed) in a small amount of water for immediate consumption. However, official information prohibits splitting or crushing the tablets with the intent of administering only a partial dose.


Q: Does Astudal contain any common allergens like gluten, dairy, or lactose?

The inactive ingredients, or excipients, in Astudal can vary depending on the manufacturer and the specific formulation. For patients concerned about common allergens such as gluten, lactose, or dairy, the full list of ingredients is available in the manufacturer's Patient Information Leaflet.


Q: What happens in the body when Astudal treatment is suddenly stopped, according to official warnings?

Studies have shown that when treatment with Astudal is stopped, blood pressure tends to return gradually to its pre-treatment baseline over a period of about 7 to 10 days. Official information reports no evidence of a rapid or dangerous rebound effect upon discontinuation.


Q: Are there any documented differences in effect between the brand-name and generic versions of Astudal?

Regulatory standards dictate that the generic and brand-name versions of amlodipine must contain the same active ingredient and be biologically equivalent. Therefore, both versions are considered by health authorities to produce the same medical effect when used as prescribed.


Q: Does the effectiveness of Astudal change or decrease with extended use?

There is no official documentation or warning to suggest that Astudal loses its effectiveness or causes a decrease in response (tolerance) with extended use. As a medication for chronic conditions, it is specifically intended for consistent, long-term administration.


Q: How is the potential for dependence or tolerance described for Astudal in regulatory documents?

Astudal is not a controlled substance and official documentation does not associate it with the development of dependence or addiction. Furthermore, it is considered a long-term treatment, indicating that the body does not typically develop tolerance that lessens its effectiveness over time.

How should Astudal be stored and disposed of?

How to Store and Dispose of Astudal?

The storage of Astudal (amlodipine besilate) tablets must strictly follow regulatory requirements to maintain product stability and quality.

Storage and Handling

Astudal must be stored at Controlled Room Temperature, which is typically defined as 15 C to 30 C (59 F to 86 F). The tablets must be kept in the container it came in, tightly closed, and the product must be protected from light and moisture. It is explicitly required that the product Do Not Freeze.

Child-Safety and Disposal

For safety, Astudal must be kept out of the sight and reach of children.

To dispose of unused or expired Astudal, users are instructed to ask a healthcare professional or pharmacist for guidance. Regulatory guidelines state the medicine should not be flushed down a toilet or poured into a drain unless specifically advised by a professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Astudal found in:

A-Z Index: